ACW Ann: Actinogen enhances XanaMIA Phase 2b Alzheimers trial - 26th Sep 2023, 9:46am

annb0t

annb0t

Top 20
ACW Ann: Actinogen enhances XanaMIA Phase 2b Alzheimers trial
Price Sensitive: Y
Date: 26th Sep 2023, 9:46am

>>> Read announcement: Google: ACW Market Announcements
 
You must log in or register to reply here.

Similar threads

annb0t
ACW Ann: Amendment to Actinogen 2023 AGM resolutions 6 to 10 - 27th Oct 2023, 1:59pm
Replies
0
Views
96
annb0t
annb0t
annb0t
ACW Ann: Actinogen September quarterly activity report & Appendix 4C - 16th Oct 2023, 9:31am
Replies
0
Views
81
annb0t
annb0t
annb0t
ACW Ann: Actinogen closes successful $10 million rights issue offer - 7th Sep 2023, 10:12am
Replies
0
Views
92
annb0t
annb0t
annb0t
ACW Ann: Actinogen FY2023 results, following the science - 30th Aug 2023, 7:04pm
Replies
0
Views
106
annb0t
annb0t
annb0t
ACW Ann: Actinogen announces $10 million rights offer - 2nd Aug 2023, 9:34am
Replies
0
Views
74
annb0t
annb0t
Top Bottom